Skip to content

Prevention of the Minor Digestive Disorders by Lactobacillus Reuteri Supplementation

Prevention of the Minor Digestive Disorders by Lactobacillus Reuteri Supplementation.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01235884
Enrollment
492
Registered
2010-11-08
Start date
2010-09-30
Completion date
2012-07-31
Last updated
2013-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minor Digestive Disorders

Keywords

gaseous colic, regurgitation and of constipation

Brief summary

Aim of the study. To evaluate if L. reuteri DSM 17938 supplementation since the first days of life can reduce the onset of gaseous colic in neonates and the onset of minor digestive disorders such as regurgitation and constipation. Study Design. Double blind, randomized, controlled, multicenter study. 492 neonates of 37-42 gestational age, breast or formula fed, will receive L. reuteri 5 drops (1x108 CFU) daily or placebo for 28 days. After the inclusion, at baseline will be performed : * Paediatric visit * antropometric valutation * number of the daily crying minutes, number of regurgitation and number of daily evacuation The patients will receive the probiotics/placebo every days for 28 days and the 29th will be repeated the following analyses: * Paediatric visit * antropometric valutation * number of daily crying minutes * numbers of regurgitation * numbers of evacuations Primary outcome : To define if Lactobacillus reuteri supplementation can reduce the onset of gaseous colic, regurgitation and of constipation. Inclusion criteria * neonates of 37-42 week gestational age and appropriate birth weight * Recruitment age: until 7 days of life * Informed consent signed Exclusion criteria * Presence of other gastrointestinal diseases. * Use of FANS, aspirin or other drugs * Use of antibiotics and/or PPIs e/o anti-H2 * Participation to other clinical trials

Interventions

DIETARY_SUPPLEMENTLactobacillus reuteri

1000000000 CFU per day (5 drops) for 28 days

DIETARY_SUPPLEMENTPlacebo

5 drops daily for 28 days

Sponsors

University of Bari
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
1 Days to 7 Days
Healthy volunteers
Yes

Inclusion criteria

* neonates of 37-42 week gestational age and appropriate birth weight * Recruitment age: until 7 days of life * Informed consent signed

Exclusion criteria

* Presence of other gastrointestinal diseases. * Use of FANS, aspirin or other drugs * Use of antibiotics and/or PPIs e/o anti-H2 * Participation to other clinical trials

Design outcomes

Primary

MeasureTime frameDescription
Reduction of the onset of gaseous colic, regurgitation and of constipation.one yearAfter the inclusion, at baseline will be performed : * Paediatric visit * antropometric valutation * number of the daily crying minutes, number of regurgitation and number of daily evacuation The patients will receive the probiotics/placebo every days for 28 days and the 29th will be repeated the following analyses: * Paediatric visit * antropometric valutation * number of daily crying minutes * numbers of regurgitation * numbers of evacuations

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026